Wanrui Lv Ke Cheng Xiaofen Li Lusi Feng Hancong Li Jia Li Chen Chang Dan Cao
10.3389/fonc.2021.759652
Front Oncol
2022 Jan 13;11:759652.
ebv-associated gastric cancer camrelizumab favorable response immunotherapy manageable toxicity programmed cell death ligand-1 (pd-l1) positive
CC BY
https://pubmed.ncbi.nlm.nih.gov/35096571/
Case Reports
PMC8791849
35096571
Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer
2022